What if improving brain health isn’t just about targeting disease—but about restoring the brain’s energy and resilience? Recent research is beginning to challenge long-held assumptions. In large clinical trials, the diabetes drug Semaglutide showed measurable effects on inflammation and biological markers linked to Alzheimer’s disease—yet those changes didn’t translate into meaningful improvements in memory or daily function. It’s a sobering reminder that shifting biomarkers alone may not be enough to change patients’ lives.
At the same time, other studies are exploring entirely different angles—like strengthening the brain before damage occurs or restoring its core energy systems. Techniques that trigger protective pathways such as Brain-Derived Neurotrophic Factor have shown the ability to reduce injury in stroke models, while emerging approaches like mitochondrial transplantation are helping rescue cellular energy failure and protect neurons in conditions like Parkinson’s disease. Together, these findings suggest a broader shift: future therapies may need to go beyond single targets and instead rebuild the brain’s capacity to function, adapt, and recover.
1. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer’s disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials
Two phase 3 trials found that oral semaglutide 14 mg did not slow cognitive or functional decline in people with early symptomatic Alzheimer’s disease, even though it improved some inflammation and cerebrospinal fluid biomarker measures. The results are still important because they clarify that biomarker changes alone may not translate into meaningful clinical benefit.
2. Remote Ischemic Preconditioning Exerts Neuroprotective Effects Via the PGC-1α/FNDC5/BDNF Pathway in Focal Brain Ischemia of Rats
In a rat stroke model, brief cycles of reduced blood flow to the limbs before ischemia helped shrink brain injury, improve neurological function, and boost protective brain signaling through the PGC-1α/FNDC5/BDNF pathway. The findings suggest a simple, noninvasive strategy that may help strengthen the brain’s resistance to ischemic damage.
3. Transplantation of encapsulated mitochondria alleviates dysfunction in mitochondrial and Parkinson’s disease models
Researchers developed a way to package and deliver healthy mitochondria into cells and tissues with high efficiency, helping rescue energy failure and cell dysfunction in mitochondrial disease models. In a mouse model of Parkinson’s disease, this approach also reduced neuron loss, improved movement, and restored mitochondrial function, pointing to a promising new form of organelle-based therapy.
If you’d like to stay informed of the latest publications and breakthroughs in neuron regeneration, join our email newsletter to the right (or below on mobile). We send out weekly updates with the latest papers and studies, as well as podcast episodes with the people driving Neuroregenerative breakthroughs.
